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Abstract
Background: Colorectal cancer screening is widely recommended, but often under-utilized. In
addition, significant demographic differences in screening utilization exist. Insurance coverage may
be one factor influencing utilization of colorectal cancer screening tests.
Methods: We conducted a retrospective analysis of claims for outpatient services for Washington
state Medicare beneficiaries in calendar year 2000. We determined the proportion of beneficiaries
utilizing screening fecal occult blood tests, flexible sigmoidoscopy, colonoscopy, or double contrast
barium enema in the overall population and various demographic subgroups. Multiple logistic
regression analysis was used to determine the relative odds of screening in different demographic
groups.
Results: Approximately 9.2% of beneficiaries had fecal occult blood tests, 7.2% had any
colonoscopy, flexible sigmoidoscopy, or barium enema (invasive) colon tests, and 3.5% had invasive
tests for screening indications. Colonoscopy accounted for 41% of all invasive tests for screening
indications. Women were more likely to receive fecal occult blood test screening (OR 1.18; 95%CI
1.15, 1.21) and less likely to receive invasive tests for screening indications than men (OR 0.80,
95%CI 0.77, 0.83). Whites were more likely than other racial groups to receive any type of
screening. Rural residents were more likely than urban residents to have fecal occult blood tests
(OR 1.20, 95%CI 1.17, 1.23) but less likely to receive invasive tests for screening indications (OR
0.89; 95%CI 0.85, 0.93).
Conclusion: Reported use of fecal occult blood testing remains modest. Overall use of the more
invasive tests for screening indications remains essentially unchanged, but there has been a shift
toward increased use of screening colonoscopy. Significant demographic differences in screening
utilization persist despite consistent insurance coverage.
Background
Screening for colorectal cancer is now recommended by
several organizations [1-5], and insurance coverage of
screening tests is becoming more widespread. For exam-
ple, the Centers for Medicare and Medicaid Services began
reimbursement for the commonly used screening tests in
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tests and 80% of charges for flexible sigmoidoscopy,
colonoscopy for high risk individuals, and barium enema.
Coverage was extended to include colonoscopy for aver-
age risk individuals in July, 2001. Despite existing guide-
lines, many eligible people are not receiving screening
tests according to current recommendations [6-9]. In
2001, only 23.5% of surveyed adults over the age of 50
had received fecal occult blood testing in the previous
year, and 43.4% had received lower endoscopy in the pre-
vious 10 years [7]. However, use of screening colonoscopy
may be increasing [10]. Age, race, insurance coverage, and
place of residence, have all been associated with utiliza-
tion [7,9,11-15]. Although lack of insurance coverage may
be one reason for under-utilization, we recently showed
that the proportion of Medicare beneficiaries receiving
invasive colorectal screening tests (defined as colonos-
copy, flexible sigmoidoscopy, or barium enema) did not
increase in 1998, immediately after introduction of Medi-
care coverage for these tests [16]. In a 9-month period dur-
ing this year, only 6.3% of Washington state Medicare
beneficiaries received fecal occult blood testing, 6.3% had
any type of invasive tests, and 3.2% had invasive screening
tests. The purpose of this study was to examine the effect
of insurance coverage on overall utilization of screening




The study was approved by the University of Washington
Institutional Review Board. We used the calendar year
2000 Physician/Supplier Part B Standard Analytic File and
the Denominator File, which are administrative databases
covering Medicare beneficiaries and maintained by the
Centers for Medicare and Medicaid Services. The Denom-
inator File contains information about date of birth, gen-
der, race, place of residence, vital status, and enrollment in
Medicare Part A, Medicare Part B or capitated health plans.
The Physician/Supplier Part B Standard Analytic File con-
tains claims data for outpatient physician and supplier
services, including the date of the visit, associated diag-
noses (coded as International Classification of Diseases
[ICD9] codes), and procedures performed (coded as Cur-
rent Procedural Terminology [CPT] or common proce-
dure [HCPCS] codes).
Patient selection
All Medicare beneficiaries listed as Washington State resi-
dents in the Denominator File in calendar year 2000 were
eligible for inclusion (n = 772,153). Beneficiaries who
were less than 65 years old (n = 132,711), who died dur-
ing the study year (n = 32,678), or who were not enrolled
in both parts A and B throughout the study year (n =
33,263) were excluded. We excluded patients enrolled in
capitated health plans during any part of the study year (n
= 170,232) because they may have received screening tests
while in these plans for which claims were not submitted.
Based on ICD9 codes in the Physician/Supplier Standard
Analytical File, we also excluded patients with a diagnosis
code for a personal history of colon polyps (V12.72, n =
683), colon or rectal cancer (V10.05 or V10.06, n = 398),
or inflammatory bowel disease (555.x, 556.x, n = 227) in
this calendar year, since these patients are at increased risk
of colorectal cancer and may need more frequent surveil-
lance. Patients without one of these diagnoses were ana-
lyzed as average risk. However, if patients did have a
history of one of these conditions, but this code was not
listed in calendar year 2000, they could have been mis-
classified as being at average risk. We did not exclude
patients with a family history of colorectal cancer, as we
felt they could not be reliably identified from the available
ICD9 diagnosis codes. We had 401,961 eligible benefici-
aries for analysis.
Identification of screening tests
We identified screening fecal occult blood tests using the
HCPCS code assigned by the Centers for Medicare and
Medicaid Services for this test (G0107). We also examined
the use of invasive colon tests (flexible sigmoidoscopy,
colonoscopy, and double contrast barium enema). How-
ever, using ICD9 codes, it can be difficult to designate a
given invasive colon test as screening or diagnostic [17].
To define tests as screening indication or diagnostic indi-
cation, we used the following algorithm, similar to our
previous study [16]. We first identified these procedures
using all CPT or HCPCS codes for colonoscopy, flexible
sigmoidoscopy, and barium enema (colonoscopy –
44388, 44389, 44392, 44393, 44394, 45378, 45380,
45383, 45384, 45385, G0105, G0121; sigmoidoscopy –
45300, 45305, 45308, 45309, 45315, 45320, 45330,
45331, 45333, 45338, 45339, G0104; barium enema –
74270, 74280, G0106, G0120, G0122). We then defined
an invasive procedure as performed for a screening indica-
tion if: 1) the procedure was coded using the relevant
HCPCS codes for screening tests; 2) ICD9 codes V76.51
(screening-malignant neoplasm-colon) or V76.41
(screening-malignant neoplasm-rectum) were associated
with the procedure; or 3) there were no ICD9 diagnosis
codes of gastrointestinal tract symptoms, weight loss, or
anemia associated with any physician visits within the
previous 3 months (abdominal pain – 787.3, 789.0x,
789.6x; altered bowel habits – 564.0, 787.x; gastrointesti-
nal bleeding – 578.x; positive fecal occult blood test –
792.1; weight loss – 783.2; iron deficiency anemia –
280.x; anemia, unspecified – 285.9). Because of this 3-
month exclusion rule, we analyzed only claims submitted
between April 1, 2000 and December 31, 2000. We ana-
lyzed only the first test performed, as later tests may havePage 2 of 8
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initial test.
Data analysis
We determined the proportion of average risk beneficiar-
ies who received screening fecal occult blood tests or who
underwent flexible sigmoidoscopy, colonoscopy, or dou-
ble contrast barium enema. For these tests, proportions
were calculated using all tests identified by all CPT and/or
HCPCS codes (all invasive tests) or only tests identified by
the algorithm described above (invasive tests for screening
indications).
We also analyzed screening test utilization in population
subgroups as defined by age, sex, race, and place of resi-
dence (urban vs. rural). We compared differences in pro-
portions of beneficiaries undergoing screening using chi-
square tests. Place of residence was defined as urban or
rural depending on the health service area in which the
patient lived. Rural health service areas include all ZIP
codes that are closest to a rural hospital, as defined by the
Washington State Department of Health. Multiple logistic
regression analysis was used to determine the relative
odds of screening in different demographic groups (Stata
8.0, Stata Corp., College Station, TX). Significance of the
regression models was tested using the log-likelihood sta-
tistic, and the method of Hosmer and Lemeshow was used
to assess goodness of fit of the regression models.
Results
Beneficiaries were predominantly white, and there were
more females than males (Table 1). In the nine-month
study period, 9.2% of Washington State Medicare benefi-
ciaries had a claim submitted for screening fecal occult
blood tests (Table 1). Fecal occult blood testing was more
common in women than in men, in beneficiaries aged 70
to 74 than in other age groups, and in rural residents than
in urban residents. Whites were the most likely to receive
screening fecal occult blood tests, and Hispanics the least
likely. These differences were all statistically significant (p
< 0.001).
Overall, 7.2% had any invasive test (colonoscopy, flexible
sigmoidoscopy, or barium enema for diagnostic or screen-
ing indications) in the 9-month study period (Table 1).
Utilization of invasive tests for screening indications was
Table 1: Demographic characteristics of beneficiaries and proportion receiving colon tests





















All subjects 401961 (100) 9.15 7.19 4.19 2.41 0.59 3.48 1.44 1.86 0.18
Sex
Male 168206 (41.8) 8.57* 7.48* 4.31* 2.64* 0.54* 4.04* 1.73* 2.12* 0.18
Female 233755 (58.2) 9.57 6.97 4.11 2.25 0.62 3.08 1.23 1.66 0.18
Age
65–69 100754 (25.1) 10.27* 7.87* 4.35* 3.05* 0.47* 4.39* 1.71* 2.51* 0.18
70–74 100454 (25.0) 10.39 8.04 4.59 2.87 0.59 4.19 1.73 2.27 0.19
75–79 90975 (22.6) 9.77 7.56 4.53 2.39 0.64 3.60 1.58 1.82 0.20
≥ 80 109778 (27.3) 6.48 5.46 3.39 1.41 0.65 1.89 0.83 0.90 0.16
Race
White 380492 (94.7) 9.36* 7.27* 4.23* 2.45* 0.59* 3.53* 1.46* 1.89* 0.18
Black 5649 (1.4) 4.66 6.30 3.77 2.05 0.48 2.81 1.26 1.49 0.07
Hispanic 2179 (0.5) 3.12 4.68 2.75 0.87 1.06 1.61 0.60 0.69 0.32
Asian 6946 (1.7) 5.83 5.64 3.43 1.86 0.30 2.58 1.04 1.41 0.13
Other 6595 (1.6) 6.60 5.78 3.71 1.77 0.29 2.56 1.12 1.35 0.09
Residence
Rural 73041 (18.2) 10.64* 6.85* 4.04 2.28 0.54 3.26* 1.37 1.72* 0.17
Urban 328920 (81.8) 8.82 7.26 4.22 2.44 0.60 3.53 1.46 1.89 0.18
* Statistically significant difference (p < 0.005).
* All flexible sigmoidoscopy, colonoscopy, or barium enema exams
† Invasive tests (flexible sigmoidoscopy, colonoscopy, or barium enema) without an associated exclusion diagnosis such as abdominal pain or anemiaPage 3 of 8
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month study period. With all invasive tests combined,
men, beneficiaries aged 70 to 74, whites, and urban resi-
dents were more likely to utilize tests than women, other
age groups, other racial groups, and rural residents,
respectively. With all invasive tests for screening indica-
tions combined, similar demographic variation in utiliza-
tion was found. Fifty-eight percent of all invasive tests and
41% of invasive tests for screening indications were
colonoscopies.
However, when examining utilization of colonoscopy,
sigmoidoscopy, and barium enema separately, some
interesting demographic differences were seen (Table 1).
Men, beneficiaries aged 70 to 74, whites, and urban resi-
dents were more likely to undergo colonoscopy. Flexible
sigmoidoscopy was more common in men, beneficiaries
age 65 to 69, whites, and urban residents. These differ-
ences were still present, but less pronounced when look-
ing at colonoscopy and flexible sigmoidoscopy for
screening indications. Use of barium enema for screening
was infrequent in both rural and urban patients. Although
Hispanics were less likely to utilize colonoscopy and sig-
moidoscopy, they were more likely to undergo barium
enema than whites.
We developed multiple logistic regression models to
determine the relative odds of receiving screening tests in
different population subgroups (Table 2). Parallel, previ-
ously published data from 1994–98 are presented for
comparison [16]. These models show that women were
more likely to receive screening fecal occult blood tests
(odds ratio 1.18; 95% confidence interval 1.15, 1.21), but
less like to receive invasive tests for screening indications
(odds ratio 0.80; 95% confidence interval 0.77, 0.83).
Beneficiaries aged 75 and over were less likely to be
screened than younger beneficiaries. For example, com-
pared with beneficiaries aged 65–69, those aged 75–79
were less likely to be screened with either fecal occult
blood tests (odds ratio 0.94; 95% confidence interval
0.91, 0.96) or with invasive tests (odds ratio 0.82; 95%
confidence interval 0.78, 0.86). Screening utilization was
also significantly lower in beneficiaries aged 80 years or
older compared with those aged 65–69. Hispanics were
less likely than whites to be screened with either fecal
occult blood tests (odds ratio 0.30; 95% confidence inter-
val 0.23, 0.38) or with the invasive tests (odds ratio 0.40;
95% confidence interval 0.28, 0.56). Rural residents were
more likely to be screened with fecal occult blood tests
(odds ratio 1.20, 95% confidence interval 1.17, 1.23), but
less likely to receive invasive tests for screening indica-
tions (odds ratio 0.89; 95% confidence interval 0.85,
0.93).
Table 2: Multivariable models of characteristics associated with utilization of colon tests
OR (95% CI) for fecal 
occult blood test, year 
2000
OR (95% CI) for any 
invasive test*, 1994–
1998
OR (95% CI) for any 
invasive test, year 
2000
OR (95% CI) for 
screening colon test*, 
1994–1998
OR (95% CI) for 
screening colon test 
year 2000
Sex
Male 1.00 1.00 1.00 1.00 1.00
Female 1.18 (1.15, 1.21) 0.99 (0.98, 1.01) 0.96 (0.93, 0.98) 0.84 (0.82, 0.86) 0.80 (0.77, 0.83)
Age
65–69 yrs 1.00 1.00 1.00 1.00 1.00
70–74 yrs 1.01 (0.98. 1.04) 1.12 (1.10, 1.14) 1.09 (0.99, 1.06) 1.05 (1.02, 1.08) 0.96 (0.92, 1.00)
75–79 yrs 0.94 (0.91, 0.96) 1.14 (1.12, 1.17) 0.96 (0.92, 0.99) 0.99 (0.96, 1.01) 0.82 (0.78, 0.86)
≥ 80 yrs 0.59 (0.57, 0.61) 0.83 (0.82, 0.85) 0.68 (0.65, 0.70) 0.60 (0.58, 0.61) 0.43 (0.41, 0.45)
Race
White 1.00 1.00 1.00 1.00 1.00
Black 0.47 (0.42, 0.54) 0.83 (0.78, 0.89) 0.83 (0.74, 0.92) 0.68 (0.62, 0.76) 0.74 (0.63, 0.87)
Hispanic 0.30 (0.23, 0.38) 0.65 (0.56, 0.76) 0.59 (0.48, 0.72) 0.48 (0.38, 0.61) 0.40 (0.28, 0.56)
Asian 0.60 (0.54, 0.66) 0.72 (0.66, 0.78) 0.74 (0.67, 0.82) 0.65 (0.58, 0.72) 0.70 (0.60, 0.81)
Other 0.67 (0.61, 0.74) 0.71 (0.68, 0.75) 0.77 (0.69, 0.85) 0.66 (0.62, 0.71) 0.40 (0.28, 0.56)
Residence
Urban 1.00 1.00 1.00 1.00 1.00
Rural 1.20 (1.17, 1.23) 0.94 (0.92, 0.96) 0.92 (0.89, 0.95) 0.92 (0.89, 0.94) 0.89 (0.85, 0.93)
* Data from 1994–98 was published previously [16].Page 4 of 8
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enema
Colonoscopy Flexible sigmoidoscopy Barium enema
Odds ratio 95% confidence 
interval
Odds ratio 95% confidence 
interval
Odds ratio 95% confidence 
interval
Sex
Male 1.00 1.00 1.00
Female 0.97 0.97, 1.00 0.89 0.86, 0.93 1.13 1.04, 1.24
Age
65–69 1.00 1.00 1.00
70–74 1.06 1.01,  1.10 0.94 0.89, 0.99 1.25 1.10, 1.41
75–79 1.04 1.00,  1.08 0.78 0.74, 0.82 1.35 1.19, 1.52
≥ 80 0.77 0.74,  0.81 0.46 0.43, 0.49 1.38 1.22, 1.55
Race
White 1.00 1.00 1.00
Black 0.87 0.76, 0.99 0.79 0.66, 0.95 0.81 0.55, 1.18
Hispanic 0.61 0.48, 0.80 0.32 0.20, 0.50 1.84 1.22, 2.78
Asian 0.78 0.69, 0.89 0.73 0.62, 0.87 0.59 0.40, 0.87
Other 0.87 0.76, 0.99 0.69 0.58, 0.83 0.49 0.31, 0.77
Residence
Rural 1.00 1.00 1.00
Urban 1.06 1.02, 1.11 1.10 1.05, 1.16 1.11 0.99, 1.24
Table 4: Multivariable models of characteristics associated with utilization of screening colonoscopy, flexible sigmoidoscopy, or barium 
enema
Colonoscopy Flexible sigmoidoscopy Barium enema
Odds ratio 95% confidence 
interval
Odds ratio 95% confidence 
interval
Odds ratio 95% confidence 
interval
Sex
Male 1.00 1.00 1.00
Female 0.74 0.71, 0.78 0.84 0.80, 0.88 0.98 0.84, 1.13
Age
65–69 1.00 1.00 1.00
70–74 1.02 0.96, 1.09 0.91 0.86, 0.96 1.06 0.86, 1.30
75–79 0.94 0.87, 1.01 0.73 0.68, 0.77 1.13 0.92, 1.40
≥ 80 0.49 0.46, 0.54 0.36 0.33, 0.39 0.90 0.73, 1.11
Race
White 1.00 1.00 1.00
Black 0.81 0.64, 1.03 0.73 0.59, 0.91 0.38 0.14, 1.02
Hispanic 0.36 0.21, 0.62 0.32 0.19, 0.53 1.72 0.82, 3.63
Asian 0.69 0.54, 0.86 0.72 0.59, 0.88 0.69 0.36, 1.34
Other 0.75 0.60, 0.95 0.68 0.55, 0.89 0.50 0.22, 1.11
Residence
Rural 1.10 1.00 1.00
Urban 1.10 1.03, 1.18 1.14 1.05, 1.18 1.09 0.90, 1.32Page 5 of 8
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to look individually at utilization of colonoscopy, sig-
moidoscopy, or barium enema for diagnostic or screening
indications (Table 3). Utilization of colonoscopy and flex-
ible sigmoidoscopy was less common in women than in
men, while women were more likely to undergo barium
enema (odds ratio 1.13, 95% confidence interval 1.04,
1.24). The odds of beneficiaries undergoing colonoscopy
initially increased slightly with age, but then decreased at
age 80 and over. The odds of undergoing sigmoidoscopy
decreased with age, while the odds of undergoing barium
enema increased with age. Hispanics were less likely than
whites to undergo colonoscopy or sigmoidoscopy, but
more likely to undergo barium enema (odds ratio 1.84,
95% confidence interval 1.22, 2.78). Other racial groups
were less likely than whites to utilize colonoscopy, flexible
sigmoidoscopy or barium enema. With inclusion of only
screening tests (Table 4), women again utilized
colonoscopy and sigmoidoscopy less often than men, but
utilized barium enema similarly (odds ratio for barium
enema 0.98, 95% confidence interval 0.84, 1.13). Utiliza-
tion of colonoscopy was relatively constant until age 80,
but then declined. Again, Hispanics were less likely than
whites to utilize colonoscopy or sigmoidoscopy for
screening indications (odds ratio for colonoscopy 0.36;
95% confidence interval 0.21, 0.62). Urban residents
were more likely than rural residents to receive colonos-
copy or sigmoidoscopy for screening indications (odds
ratio for colonoscopy 1.10; 95% confidence interval 1.03,
1.18), but utilized barium enema similarly.
Discussion
We previously showed that colorectal cancer screening
tests are under-utilized and that utilization did not
increase shortly after introduction of the Medicare
screening benefit [16]. In this study, we extend these find-
ings and examine the effect on utilization after 2 to 3 years
of insurance coverage. Although utilization of fecal occult
blood testing increased moderately between 1998 and
2000 (6.30% vs. 9.15% over 9 months, respectively), uti-
lization of more invasive tests remained infrequent
(6.26% in 1998 vs. 7.19% in 2000 receiving any invasive
test; 3.17% in 1998 vs. 3.48% in 2000 receiving invasive
tests for screening indications over 9 months). This was
true for all demographic subgroups examined. However,
there was some shift in the type of invasive procedure
done, with increasing use of colonoscopy compared with
flexible sigmoidoscopy and barium enema. In 2000, 58%
of all invasive tests and 41% of invasive tests for screening
indications were colonoscopies, compared to 47% and
35% in 1998, respectively. Medicare coverage for screen-
ing colonoscopy in average risk beneficiaries did not
begin until July 2001, and therefore most colonoscopy
exams during our study were likely done in high risk
patients. Utilization of screening colonoscopy may have
increased even further after this change in reimbursement
policies to cover average risk individuals.
In addition, we show that insurance coverage for screen-
ing does not eliminate disparities in screening utilization.
In fact, disparities actually increased over time in some
instances. Compared to 1994–1998 [16], the relative
odds of any invasive testing for Hispanics versus whites
actually decreased in 2000, while the effect for invasive
tests for screening indications in different racial groups
was mixed (Table 2). Disparities related to gender and
place of residence were essentially unchanged between
1994–8 and 2000. These findings extend those of other
studies in the general population [12,14], where universal
insurance coverage of screening was not present, and stud-
ies of previous years in Medicare beneficiaries [13,15].
The precise reasons for the observed demographic dispar-
ities in screening are unknown. The sex and race-related
disparities are consistent with other data showing differ-
ential use of medical services in general in these popula-
tion subgroups. Screening in general was most common
in beneficiaries age 65 to 74. As the potential benefit of
screening decreases with age and shorter life expectancy,
the age-related decrement in screening after age 75 may be
clinically appropriate. Regarding geographic differences,
the availability of screening services, especially for the
invasive and more resource intensive tests such as colon-
oscopy and sigmoidoscopy, may be greater in urban than
in rural areas. Fecal occult blood testing is less resource
intensive and is likely to be more available in rural areas,
potentially explaining some of the geographic differences
in screening.
Projecting these data out over a longer period gives a more
complete picture of utilization differences. For example,
3.5% of whites, 2.8% of blacks, and 1.6% of Hispanics
had invasive screening tests done over the 9-month study
period. Assuming constant screening rates, over a 5-year
period, 23% of whites would undergo invasive tests, com-
pared to only 19% of blacks and 11% of Hispanics. These
differences are further magnified if fecal occult blood test
utilization is also considered. These screening disparities
may contribute to the known differences in colorectal can-
cer incidence and survival in different racial groups
[18,19].
This study has several limitations. First, we cannot clearly
separate the effects of Medicare coverage from secular
trends towards increasing utilization of screening tests.
Second, we used administrative claims databases to assess
health services utilization. Although the accuracy of cod-
ing for the diagnoses and procedures studied here is not
established, claims coding surgical services and proce-
dures is fairly reliable and accurate [20-24]. Third, we ana-Page 6 of 8
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necessarily be generalizable to other regions. In particular,
the number of minorities in this study was relatively
small, and the confidence intervals for minority groups in
the multiple logistic regression models were wide. How-
ever, patterns of utilization of colorectal cancer screening
tests were similar in Kansas Medicare beneficiaries [9,12].
Another study looking at national trends in colorectal
tests in Medicare beneficiaries found that use of sig-
moidoscopy, barium enema, and fecal occult blood test-
ing declined over a similar period, while colonoscopy
utilization increased [25].
Our study only included patients age 65 and older, and we
did not assess utilization in patients younger than this.
This was a cross-sectional study, and patients who may
have previously been screened with procedures that are
not recommended annually would have been classified as
unscreened in our analysis. Utilization of colonoscopy
and colonoscopy practice patterns may have changed
substantially since 2000 [26-28]. Lastly, we excluded
patients who enrolled in capitated health plans, where
health services utilization patterns may differ from those
in traditional fee-for-service plans [29,30]. Screening fre-
quency should also be studied within these health plans.
Although we developed an algorithm to distinguish
screening from diagnostic tests, we cannot be certain that
tests we designated as screening were truly intended as
screening tests. We excluded patients with physician visits
for gastrointestinal symptoms over the prior 3 months,
but it may take longer to have a colonoscopy scheduled
for these indications. This may influence our estimates of
screening frequency. In our previous study, we found that
82% of procedures designated as screening from the
HCPCS codes would have been classified as screening
from our algorithm [16]. However, even if all colonoscop-
ies, flexible sigmoidoscopies, or barium enemas done
were intended as screening, only 7.2% of the study popu-
lation would have had an invasive screening test during
the 9-month study period, or 9.6% per year. Since not all
invasive tests done are intended for screening, we believe
that less than 7% of our study population had invasive
screening tests during the 9-month study period.
This study extends our previous work and shows that pro-
vision of insurance coverage of screening tests does not
necessarily increase utilization of such tests in the
medium term. Even 2 to 3 years after beginning universal
coverage and widespread publicity about colorectal cancer
screening [31], screening rates changed only modestly,
and demographic differences in screening utilization
remained. Thus, insurance coverage may be only one
small factor affecting patients' decisions to undergo color-
ectal cancer screening [32]. We did find a moderate shift
towards use of the most expensive test, colonoscopy, over
time. It may be that the more ready availability of colon-
oscopy services in urban areas influences patients' or pro-
viders' decisions to use this form of screening. Conversely,
female or non-white beneficiaries may be more reluctant
to undergo invasive screening tests, or providers may be
less likely to offer invasive tests to these subgroups. In
addition, out-of-pocket costs for screening tests may still
be prohibitive for some populations, affecting screening
utilization. We did not have information about private
insurance or indirect costs which could influence deci-
sions about screening. These aspects of disparities in
screening utilization cannot be addressed using adminis-
trative claims data. Therefore, further efforts should be
made to identify and address additional barriers to and
preferences about colorectal cancer screening in the gen-
eral Medicare population, and especially in underserved
subgroups.
Conclusion
Overall utilization of colorectal cancer screening tests
increased only modestly 2 to 3 years after institution of
Medicare coverage, but there was a shift towards screening
colonoscopy and away from less invasive tests. Demo-
graphic differences in screening persisted despite consist-
ent insurance coverage.
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